Home Must Read Articles

Must Read Articles

Highlights in Development: September 2019

In September 2019, a number of articles discussing antibody-drug conjugates were published in a variety of journals.  Here is...

ADC-based Conditioning with Platelet-directed HSC-based FVIII Gene Therapy Shows Promise in Hemophilia Treatment

Gene therapy for hemophilia, a condition in which the ability of the blood to clot is severely reduced, as...
Journal Articles - Paper and Labptop

Enabling Heterobifunctional, Dual “Click,” Antibody Modification via Microbial Transglutaminase

With 5 approved and commercially available antibody-drug conjugates, this class of therapeutics, combining the efficacy of small-molecule therapeutics with...
Featured Image: Journal + glasses. Courtesy: © 2017 - 2019. Fotolia. Used with permission.

Identifying Regulators of Antibody–drug Conjugate Toxicity

Antibody–drug conjugates or ADCs selectively deliver a a cytotoxic payload to target cancer cells, making them important anti-cancer therapeutics....
Uppsala University in Uppsala, Sweden. Courtesy: Mikael Wallerstedt

Using a Hydrophilic Spacer to Reduce Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates

In the development of novel drug conjugates alternatives to monoclonal antibodies (mAbs) have started to emerge. While antibodies have...

Using Middle-Down Mass Spectrometry to Identify the Drug Conjugation Site of a Site-Specific Antibody-Drug-Conjugate

Antibody–drug conjugates are among the fastest growing classes of anti-cancer therapeutics.With the 5 approved and commercially available agents, and nearly...
A new technology enables a simple way of connecting the cytsteine residues (SH) of a tumor-sensing antibody (yellow) to the cytotoxic payload. The emerging linker is highly stable during blood circulation and enables therefore a safe transport to the tumor side. Image courtesy: Barth van Rossum/FMP

A Superglue for ADCs: Connecting the Cytsteine Residues of a Tumor-sensing Antibody to a...

The Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU) hve developed an innovative technology designed to make...

Immunocapture-liquid Chromatography/Mass Spectrometry in Simultaneous Quantification of Total Antibody and ADC for XMT-1522 in...

XMT-1522, an investigational antibody-drug conjugate (ADC) being developed by Mersana Therapeutics and Takeda, represents the first Dolaflexin®-based, cleavable ADC...
One red Dutch tulip

Trastuzumab Duocarmazine for Treatment of HER2-Expressing Breast Cancer

Trastuzumab duocarmazine* (SYD985; Synthon) is a novel antibody-drug conjugate composed of the recombinant humanized anti-epidermal growth factor receptor 2...

A Review of Cleavable Linkers

With 5 commercially available antibody-drug conjugates (ADCs) an nearly 100 novel agents in developments - from early discovery to...